You have free access to this content

Cancer

Cover image for Vol. 120 Issue 8

15 April 2014

Volume 120, Issue 8

Pages 1131–1285

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Review Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
      Genomic tools in acute myeloid leukemia: From the bench to the bedside (pages 1134–1144)

      Brian S. White and John F. DiPersio

      Version of Record online: 28 JAN 2014 | DOI: 10.1002/cncr.28552

      • image
      • image

      The authors review the contributions of next-generation sequencing in discovering mutations in acute myeloid leukemia, elucidating their prognostic and biologic significance, and revealing disease oligoclonality. Next-generation sequencing is poised for clinical application, although challenges remain.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. Disease Site

      Chest and Lung Disease
      You have full text access to this OnlineOpen article
      A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib (pages 1145–1154)

      Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, Shirish M. Gadgeel, Fadlo R. Khuri, Jeff A. Engelman, Marianna Koczywas, Arun Rajan, Alicyn K. Campbell, Diana Gernhardt, Ana Ruiz-Garcia, Stephen Letrent, Jane Liang, Ian Taylor, Joseph P. O'Connell and Pasi A. Jänne

      Version of Record online: 5 FEB 2014 | DOI: 10.1002/cncr.28561

      • image
      • image
      • image

      This study investigated the efficacy and safety of dacomitinib in advanced, refractory non–small cell lung cancer (NSCLC), selecting for patients with KRAS wild-type tumors to exclude those least likely, and simultaneously enrich for those most likely, to benefit from therapy. Although the observed response rate was low, a number of patients experienced prolonged disease control accompanied by rapid and durable lung cancer symptom relief, suggesting that dacomitinib has relevant activity against KRAS wild-type NSCLC.

    2. Endocrine Disease
      You have free access to this content
      Comparison of secondary and primary thyroid cancer in adolescents and young adults (pages 1155–1161)

      Melanie Goldfarb and David R. Freyer

      Version of Record online: 24 FEB 2014 | DOI: 10.1002/cncr.28463

      • image

      Adolescents and young adults who develop thyroid cancer as a second malignancy have a significantly decreased overall survival compared to adolescents and young adults with primary thyroid cancer. Multiple demographic and tumor differences exist between these 2 cohorts.

    3. Gastrointestinal Disease
      You have free access to this content
      Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare data, 1998-2007 (pages 1162–1170)

      Alex B. Haynes, Y. Nancy You, Chung-Yuan Hu, Cathy Eng, E. Scott Kopetz, Miguel A. Rodriguez-Bigas, John M. Skibber, Scott B. Cantor and George J. Chang

      Version of Record online: 28 JAN 2014 | DOI: 10.1002/cncr.28545

      • image
      • image

      The authors examine treatment patterns within the Medicare-linked Surveillance, Epidemiology, and End Results database and demonstrate significant variation in adjuvant therapy use based on treatment response that is not supported by the current treatment guidelines. These data will inform further study of the causes of this variation and the impact on treatment outcomes.

    4. You have free access to this content
      Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy (pages 1171–1177)

      Eric A. Mellon, Gregory M. Springett, Sarah E. Hoffe, Pamela Hodul, Mokenge P. Malafa, Kenneth L. Meredith, William J. Fulp, Xiuhua Zhao and Ravi Shridhar

      Version of Record online: 3 JAN 2014 | DOI: 10.1002/cncr.28543

      • image

      For eligible patients with localized pancreatic cancer, surgery and chemotherapy are standards of care. The authors use the Surveillance, Epidemiology, and End Results (SEER) database to identify additional survival benefits from postoperative radiation therapy.

    5. You have free access to this content
      Stage-specific associations between beta blocker use and prognosis after colorectal cancer (pages 1178–1186)

      Lina Jansen, Michael Hoffmeister, Volker Arndt, Jenny Chang-Claude and Hermann Brenner

      Version of Record online: 10 JAN 2014 | DOI: 10.1002/cncr.28546

      • image

      This first detailed investigation of the association between beta blocker use at diagnosis and colorectal cancer prognosis showed that beta blocker use was not associated with prognosis after colorectal cancer in the total study population. However, in stage-specific analyses, beta blocker use was significantly associated with a prolongation of survival of 18 months for patients with stage IV disease.

    6. Gynecologic Oncology
      You have free access to this content
      Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer (pages 1187–1193)

      Angelica Nogueira-Rodrigues, Giulliana Moralez, Rachele Grazziotin, Claudio C. Carmo, Isabele A. Small, Flavia V.G. Alves, Marcelo Mamede, Felipe Erlich, Celia Viegas, Sergio A. Triginelli and Carlos G. Ferreira

      Version of Record online: 10 MAR 2014 | DOI: 10.1002/cncr.28471

      • image

      According to this phase 2 trial, erlotinib combined with chemoradiation is safe and exerts significant activity in patients with locally advanced cervical cancer. To the best of the authors' knowledge, this is the first study to date to demonstrate that a target agent has promising activity in this disease.

    7. Discipline

      Clinical Trials
      You have free access to this content
      A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061 (pages 1194–1202)

      Michelle A. Rudek, Page C. Moore, Ronald T. Mitsuyasu, Bruce J. Dezube, David Aboulafia, John Gerecitano, Ryan Sullivan, Mary E. Cianfrocca, David H. Henry, Lee Ratner, Missak Haigentz, Afshin Dowlati, Richard F. Little, Susan Percy Ivy and John F. Deeken

      Version of Record online: 28 JAN 2014 | DOI: 10.1002/cncr.28554

      Given the rising incidence of non–acquired immunodeficiency syndrome–defining cancers in patients with the human immunodeficiency virus (HIV), the increasing treatment options for patients with cancer with new targeted therapies, and concerns about drug-drug interactions between HIV agents and chemotherapy, clinical studies are needed to guide patient care. In the current phase 1 study, which to our knowledge is the first of its kind to investigate the combination of highly active antiretroviral therapy (HAART) with a targeted agent (sunitinib), it was found that patients receiving ritonavir-based HAART should be treated with a lower dose of sunitinib, whereas patients receiving other HAART regimens can be treated with the standard dose.

    8. Disparities Research
      You have free access to this content
      Uncovering nativity disparities in cancer patterns: Multiple imputation strategy to handle missing nativity data in the Surveillance, Epidemiology, and End Results data file (pages 1203–1211)

      Jane R. Montealegre, Renke Zhou, E. Susan Amirian and Michael E. Scheurer

      Version of Record online: 16 JAN 2014 | DOI: 10.1002/cncr.28533

      • image

      Multiple imputation using variables available in the Surveillance, Epidemiology, and End Results (SEER) data file can be used to accurately detect foreign-born status among the large percentage of SEER cases with missing birthplace information. This strategy will aid researchers in disaggregating analyses by nativity status and uncover important nativity disparities in regard to cancer diagnosis, treatment, and survival.

    9. You have free access to this content
      Insurance status and distant-stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010 (pages 1212–1219)

      Anthony S. Robbins, Catherine C. Lerro and Ronald D. Barr

      Version of Record online: 28 JAN 2014 | DOI: 10.1002/cncr.28568

      In a national sample of nearly 260,000 adolescent and young adult patients with cancer, insurance status was found to be a strong predictor of distant-stage disease at the time of diagnosis in multivariate models that adjusted for age, sex, race/ethnicity, facility type, ZIP code-based income and education level, and US Census region. The adolescent and young adult age group (those aged 15-39 years) has the highest percentage of individuals without health insurance.

    10. You have free access to this content
      Insurance status is related to diffuse large B-cell lymphoma survival (pages 1220–1227)

      Xuesong Han, Ahmedin Jemal, Christopher R. Flowers, Helmneh Sineshaw, Loretta J. Nastoupil and Elizabeth Ward

      Version of Record online: 28 JAN 2014 | DOI: 10.1002/cncr.28549

      • image
      • image

      Uninsured and Medicaid-insured patients with diffuse large B-cell lymphoma have inferior survival compared with privately insured patients. These associations can be explained in part because uninsured/Medicaid patients with diffuse large B-cell lymphoma present with more advanced-stage disease and comorbid illnesses and less commonly receive standard treatment.

    11. Medical Oncology
      You have free access to this content
      Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer (pages 1228–1236)

      Xianhan Jiang, Xun Li, Hai Huang, Funeng Jiang, Zhuoyuan Lin, Huichan He, Yanru Chen, Fei Yue, Jing Zou, Yongzhong He, Pan You, Wenwei Wang, Weiqing Yang, Haibo Zhao, Yiming Lai, Fen Wang, Weide Zhong and Leyuan Liu

      Version of Record online: 3 JAN 2014 | DOI: 10.1002/cncr.28551

      • image
      • image
      • image

      Leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) is a mitochondrion-associated autophagy inhibitor that protects mitochondria from degradation. To the authors' knowledge, the current study is the first to demonstrate that high levels of LRPPRC are associated with poor prognosis in patients with late-stage prostate cancer.

    12. Outcomes Research
      You have free access to this content
      Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty (pages 1237–1245)

      Andrés M. Acevedo, Alexandra Gómez, Henry A. Becerra, Ana P. Ríos, Paula C. Zambrano, Evelyn P. Obando, Arturo J. Martí-Carvajal, Hernán Carranza, Carlos A. Vargas, Jorge M. Otero, Ludovic Reveiz and Andrés F. Cardona

      Version of Record online: 31 DEC 2013 | DOI: 10.1002/cncr.28539

      • image
      • image
      • image

      This descriptive analysis of Latin American research in hematology and oncology indicates that, although research is increasing in Latin America in this field, the contribution is limited to a few countries. More extensive analysis is needed to identify regional and local problems and to highlight potential areas for improvement.

    13. You have free access to this content
      Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer (pages 1246–1254)

      Jason D. Wright, Cande V. Ananth, Jennifer Tsui, Sherry A. Glied, William M. Burke, Yu-Shiang Lu, Alfred I. Neugut, Thomas J. Herzog and Dawn L. Hershman

      Version of Record online: 17 JAN 2014 | DOI: 10.1002/cncr.28508

      • image
      • image

      Use of neoadjuvant therapy has increased over time. Survival with neoadjuvant chemotherapy compares favorably with primary surgery in elderly women in the United States.

    14. Pediatric Oncology
      You have free access to this content
      Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis (pages 1255–1262)

      Ting-Chi Yeh, Hsi-Che Liu, Jen-Yin Hou, Kuan-Hao Chen, Ting-Huan Huang, Ching-Yi Chang and Der-Cherng Liang

      Version of Record online: 10 JAN 2014 | DOI: 10.1002/cncr.28524

      For patients with childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) who are receiving intensive chemotherapy, prophylaxis with antibiotic and antifungal agents can significantly reduce the rate of life-threatening infections in patients with ALL who are undergoing induction chemotherapy, bloodstream infections in patients with AML who are being treated with high-dose chemotherapy, and invasive fungal infections in patients with AML who are receiving modest-dose chemotherapy. Prophylaxis regimens also have been found to reduce the number of episodes of febrile neutropenia, the length of stay in the intensive care unit for patients with ALL, mortality caused by severe infections in patients with AML, and cost.

    15. Quality of Life
      You have free access to this content
      Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment (pages 1263–1271)

      Matthew J. Resnick, Daniel A. Barocas, Alicia K. Morgans, Sharon E. Phillips, Vivien W. Chen, Matthew R. Cooperberg, Michael Goodman, Sheldon Greenfield, Ann S. Hamilton, Karen E. Hoffman, Sherri H. Kaplan, Lisa E. Paddock, Antoinette M. Stroup, Xiao-Cheng Wu, Tatsuki Koyama and David F. Penson

      Version of Record online: 7 FEB 2014 | DOI: 10.1002/cncr.28563

      • image
      • image

      Urinary, sexual, bowel, and hormonal dysfunction is common among patients with newly diagnosed prostate cancer, even before they receive treatment. In the process of considering the population-level decision-making with respect to prostate cancer screening and treatment, these data will serve as a baseline upon which to define the population “at risk” for suffering treatment-related harms.

    16. Radiation Oncology
      You have free access to this content
      Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710 (pages 1272–1280)

      John P. Christodouleas, Brian C. Baumann, Jiwei He, Wei-Ting Hwang, Kai N. Tucker, Justin E. Bekelman, Catherine M. Tangen, Seth P. Lerner, Thomas J. Guzzo and S. Bruce Malkowicz

      Version of Record online: 3 JAN 2014 | DOI: 10.1002/cncr.28544

      • image
      • image
      • image

      A revised risk model that includes surgical margin status, pathologic tumor classification, and the number of lymph nodes identified is used to stratify local failure outcomes in 2 significantly different radical cystectomy cohorts. This model may represent an important step toward developing rigorous clinical trials of adjuvant locoregional therapy for bladder cancer.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content
    2. You have free access to this content
  5. Erratum

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    6. Erratum
    1. You have free access to this content

SEARCH

SEARCH BY CITATION